Nature Communications (Jul 2024)

WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis

  • Fernando Rodríguez Pérez,
  • Dean Natwick,
  • Lauren Schiff,
  • David McSwiggen,
  • Alec Heckert,
  • Melina Huey,
  • Huntly Morrison,
  • Mandy Loo,
  • Rafael G. Miranda,
  • John Filbin,
  • Jose Ortega,
  • Kayla Van Buren,
  • Danny Murnock,
  • Arnold Tao,
  • Renee Butler,
  • Kylie Cheng,
  • William Tarvestad,
  • Zhengjian Zhang,
  • Eric Gonzalez,
  • Rand M. Miller,
  • Marcus Kelly,
  • Yangzhong Tang,
  • Jaclyn Ho,
  • Daniel Anderson,
  • Charlene Bashore,
  • Stephen Basham

DOI
https://doi.org/10.1038/s41467-024-50178-3
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Synthetic lethality provides an attractive strategy for developing targeted cancer therapies. For example, cancer cells with high levels of microsatellite instability (MSI-H) are dependent on the Werner (WRN) helicase for survival. However, the mechanisms that regulate WRN spatiotemporal dynamics remain poorly understood. Here, we used single-molecule tracking (SMT) in combination with a WRN inhibitor to examine WRN dynamics within the nuclei of living cancer cells. WRN inhibition traps the helicase on chromatin, requiring p97/VCP for extraction and proteasomal degradation in a MSI-H dependent manner. Using a phenotypic screen, we identify the PIAS4-RNF4 axis as the pathway responsible for WRN degradation. Finally, we show that co-inhibition of WRN and SUMOylation has an additive toxic effect in MSI-H cells and confirm the in vivo activity of WRN inhibition using an MSI-H mouse xenograft model. This work elucidates a regulatory mechanism for WRN that may facilitate identification of new therapeutic modalities, and highlights the use of SMT as a tool for drug discovery and mechanism-of-action studies.